Irish HSE to decide on funding for Friedreich's ataxia treatment

The Irish Health Service Executive (HSE) is set to issue a decision on funding for a drug treating Friedreich's ataxia following intense political pressure. It remains uncertain if the decision will result in immediate approval or further review, a move that carries significant implications for patient access to rare disease therapies.